Clinical trials: Allergic Bronchopulmonary Aspergillosis
ABPA
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
- Trial name
- NCT05667662
- Testing
- Itraconazole Powder
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 8 people
- Sponsor
- Pulmatrix Inc.
Aspergillosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
- Trial name
- NCT02715570
- Testing
- PC945 - single doses, PC945 - repeat doses
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
- Trial name
- NCT01222273
- Testing
- cholecalciferol (Vitamin D3)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pittsburgh
ABPA, Allergic Bronchopulmonary Aspergillosis
ML-Based ABPA Recurrence Prediction and Clinical Utility
This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Acute Exacerbation
- Trial name
- ABPA-ML (NCT07714863)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a strategy with a maintenance treatment and a conventional strategy without antifungal maintenance therapy.
- Trial name
- NEBULAMB (NCT02273661)
- Testing
- Liposomal amphotericin B (Ambisome®)
- Where
- France
- Volunteers
- 174 people
- Sponsor
- Poitiers University Hospital
Allergic Bronchopulmonary Aspergillosis
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic…
- Trial name
- NCT03960606
- Testing
- PUR1900
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 7 people
- Sponsor
- Pulmatrix Inc.
ABPA, Biologics
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.
- Conditions
- ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA), Cohort Study
- Trial name
- NCT07362693
- Testing
- Biologic Agent
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
ABPA, Allergic Bronchopulmonary Aspergillosis
Fungal Status and Prognosis in ABPA
This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Colonization
- Trial name
- ABPAFUNGAL (NCT07690345)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Qianfoshan Hospital
Cystic Fibrosis, Chit1
Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients
Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease in CF Patients. Aim: To evaluate the link between CHIT1 duplication in CF patients and the predisposition to ABPA or persistent…
- Trial name
- NCT01572870
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rambam Health Care Campus
Allergic Bronchopulmonary Aspergillosis (ABPA)
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and…
- Trial name
- NCT07040332
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals